8-K: Aurinia Pharmaceuticals Reports Strong Q3, Raises 2025 Guidance

Aurinia Pharmaceuticals Inc. announced robust third-quarter 2025 financial results, driven by strong LUPKYNIS sales, and raised its full-year 2025 revenue and product sales guidance.

Summary

• Total revenue for Q3 2025 was $73.5 million, an 8% increase from $67.8 million in Q3 2024.
• Net product sales of LUPKYNIS reached $70.6 million in Q3 2025, up 27% from $55.5 million in Q3 2024.
• Net income for Q3 2025 surged to $31.6 million, a 119% increase from $14.4 million in Q3 2024.
• Diluted earnings per share for Q3 2025 were $0.23, up 130% from $0.10 in Q3 2024.
• Cash flows from operating activities for Q3 2025 were $44.5 million, a 162% increase from $17.0 million in Q3 2024.
• For the nine months ended September 30, 2025, total revenue was $205.9 million, up 17% from $175.3 million in the same period of 2024.
• Net product sales of LUPKYNIS for the nine months ended September 30, 2025, were $197.2 million, up 24% from $158.6 million in the same period of 2024.
• Net income for the nine months ended September 30, 2025, was $76.4 million, a 1677% increase from $4.3 million in the same period of 2024.
• Diluted earnings per share for the nine months ended September 30, 2025, were $0.55, up 1733% from $0.03 in the same period of 2024.
• Cash flows from operating activities for the nine months ended September 30, 2025, were $90.0 million, up 529% from $14.3 million in the same period of 2024.
• Cash, cash equivalents, restricted cash, and investments stood at $351.8 million as of September 30, 2025.
• Full-year 2025 total revenue guidance was raised to a range of $275 million to $280 million, and net product sales guidance was raised to $265 million to $270 million.
• New analyses of LUPKYNIS clinical studies (AURORA 1, AURORA 2, AURA-LV) reinforce its robust clinical benefit, showing a statistically significant and clinically meaningful reduction in the risk of Renal-Related Events or Death.
• Aritinercept, a dual BAFF/APRIL inhibitor, showed positive Phase 1 results, demonstrating robust and long-lasting reductions in immunoglobulins (IgA up to 48%, IgM up to 55%, IgG up to 20%) and was well tolerated.

Sentiment

Score: 9

Explanation: The filing indicates very strong financial performance with significant growth in revenue, net income, and cash flow. The company also raised its full-year guidance for the second time, and its pipeline asset, aritinercept, shows promising Phase 1 results with plans for further clinical development. These factors collectively point to a highly positive outlook.

Positives

• LUPKYNIS net product sales grew 27% in Q3 2025 to $70.6 million, demonstrating strong market momentum.
• Total revenue increased by 8% in Q3 2025 to $73.5 million and 17% for the nine months to $205.9 million.
• Net income saw significant growth, increasing 119% in Q3 2025 to $31.6 million and a remarkable 1677% for the nine months to $76.4 million.
• Diluted earnings per share rose 130% in Q3 2025 to $0.23 and 1733% for the nine months to $0.55.
• Cash flows from operating activities increased substantially by 162% in Q3 2025 to $44.5 million and 529% for the nine months to $90.0 million.
• Full-year 2025 total revenue guidance was raised for the second time this year, now projected between $275 million and $280 million.
• Full-year 2025 net product sales guidance was also raised to a range of $265 million to $270 million.
• New LUPKYNIS data analyses reinforce its robust clinical benefit, showing a statistically significant and clinically meaningful reduction in the risk of Renal-Related Events or Death (HR 0.466, P-value 0.0012).
• Aritinercept's Phase 1 study demonstrated it was well tolerated with no treatment-related Grade 3 adverse events or serious adverse events.
• Single doses of aritinercept led to robust and long-lasting reductions in immunoglobulins (IgA up to 48%, IgM up to 55%, IgG up to 20%), supporting once-monthly dosing.

Negatives

• License, collaboration, and royalty revenue decreased significantly in Q3 2025 to $2.8 million from $12.3 million in Q3 2024, primarily due to a $10.0 million milestone payment in 2024 associated with LUPKYNIS regulatory approval in Japan.
• Cash, cash equivalents, restricted cash, and investments slightly decreased to $351.8 million as of September 30, 2025, from $358.5 million at December 31, 2024, partly due to share repurchases.

Risks

• Actual outcomes could differ materially from current expectations due to substantial risks and uncertainties.
• Risks are associated with LUPKYNIS net product sales.
• Risks are associated with the timing of clinical study results.
• Other risks and uncertainties are identified in the company's filings with the U.S. Securities and Exchange Commission, including the most recent Annual Report on Form 10-K.

Future Outlook

The company is optimistic about continued LUPKYNIS sales momentum, driven by its inclusion in American College of Rheumatology lupus nephritis treatment guidelines. Management anticipates initiating clinical studies for aritinercept in two autoimmune diseases by the end of 2025, following positive Phase 1 results. Full-year 2025 total revenue guidance has been raised to $275 million to $280 million, and net product sales guidance to $265 million to $270 million, reflecting confidence in ongoing performance.

Management Comments

• "LUPKYNIS sales experienced continued momentum following last year's update to the American College of Rheumatology lupus nephritis treatment guidelines, which recommend the incorporation of drugs like LUPKYNIS into first-line therapy in order to preserve kidney function."
• "Additionally, we are excited about the positive results from our Phase 1 study of aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) and look forward to initiating clinical studies in two autoimmune diseases by the end of this year."

Industry Context

Aurinia's strong LUPKYNIS sales growth reflects increasing adoption of advanced therapies in lupus nephritis, particularly following guideline updates recommending its use as first-line therapy. This positions LUPKYNIS favorably against older treatments and highlights the growing demand for effective, targeted autoimmune disease management. The advancement of aritinercept, a dual BAFF/APRIL inhibitor, into clinical studies aligns with a broader industry trend towards developing more comprehensive B-cell modulating therapies, potentially offering a differentiated profile compared to single-target inhibitors in the competitive autoimmune landscape.

Comparison to Industry Standards

• Aritinercept's Phase 1 results show mean IgA reductions of up to 48%, IgM reductions of up to 55%, and IgG reductions of up to 20% at Day 28 following a single dose (225 mg SC).
• Compared to other BAFF/APRIL inhibitors in cross-trial comparisons of SAD studies (no head-to-head clinical studies):
• For IgA reduction at Day 28: Aritinercept (-48%) appears competitive with Povetacicept (Vertex, -43%) and Sibeprenlimab (Otsuka, -41%), and superior to Atacicept (Vera, -10%) and Telitacicept (RemeGen/Vor Bio, 7%).
• For IgM reduction at Day 28: Aritinercept (-55%) appears competitive with Povetacicept (Vertex, -52%) and superior to Sibeprenlimab (Otsuka, -39%), Atacicept (Vera, -17%), and Telitacicept (RemeGen/Vor Bio, 6%).
• For IgG reduction at Day 28: Aritinercept (-20%) appears competitive with Povetacicept (Vertex, -19%) and superior to Sibeprenlimab (Otsuka, -13%) and Telitacicept (RemeGen/Vor Bio, 7%). Atacicept showed no apparent reduction in serum IgG levels.

Stakeholder Impact

• Shareholders are likely to benefit from strong financial performance, increased guidance, and the company's share repurchase program ($98.2 million for 12.2 million shares in nine months).
• Patients with lupus nephritis may benefit from the continued availability and reinforced efficacy of LUPKYNIS, especially with its recommendation in first-line therapy guidelines.
• Potential future patients with autoimmune diseases could benefit from the advancement of aritinercept into clinical studies, offering new treatment options.

Next Steps

• Initiate clinical studies of aritinercept in two autoimmune diseases by the end of 2025.
• Host a webcast and conference call on November 4, 2025, at 8:30 a.m. ET to discuss results and business progress.

Key Dates

Recommendation

The company has demonstrated exceptional financial performance with significant year-over-year growth in key metrics like net product sales, net income, and cash flow from operations. The decision to raise full-year guidance for both total revenue and net product sales for the second time this year signals strong underlying business momentum and management confidence. Furthermore, the positive Phase 1 results for aritinercept and the plan to advance it into clinical studies for two autoimmune diseases by year-end provide a promising pipeline catalyst. The reinforced clinical benefit of LUPKYNIS also strengthens its market position. These factors collectively present a compelling investment case for substantial upside potential.

Keywords

Aurinia Pharmaceuticals, LUPKYNIS, voclosporin, lupus nephritis, autoimmune diseases, aritinercept, BAFF inhibitor, APRIL inhibitor, Q3 2025 earnings, financial results, biopharmaceutical, clinical trials, FDA approval, renal response